Wanbury has secured approval from the European Directorate for the Quality of Medicines and Healthcare (EDQM) for its new product Rivaroxaban API. According to the company's press release issued on August 13, 2026, this approval represents a significant milestone for the company's European market expansion strategy. The EDQM approval specifically enables the company to meet customer demand from the European Union and other countries accepting CEP, strengthening its regulatory compliance across key international markets. Rivaroxaban is an anticoagulant used in the management of blood clotting disorders, making this approval particularly valuable for the European pharmaceutical market.
Wanbury has achieved Drug Master File (DMF) clearance for Paroxetine HCI and Metformin HCI from the US Food and Drug Administration (USFDA). As reported in the company's press release, these regulatory approvals demonstrate the company's ability to meet international quality standards across multiple jurisdictions. Paroxetine HCl is an antidepressant, and Metformin HCl is widely prescribed for type 2 diabetes management, representing significant global markets with consistent demand. The USFDA DMF clearances were received while ANDA (Abbreviated New Drug Application) reviews are underway for multiple customers, facilitating supply chain integration for finished dosage form manufacturers in the United States.
The combined regulatory approvals position Wanbury to serve diverse international markets with its pharmaceutical API products. According to the company's press release, these approvals span two of the most stringent pharmaceutical regulatory frameworks globally and are critical for expanding the company's addressable market. The EDQM approval for Rivaroxaban API specifically addresses European market requirements, while the USFDA clearances strengthen the company's position in the American pharmaceutical market. These approvals collectively enhance Wanbury's regulatory portfolio and market access capabilities across key global pharmaceutical jurisdictions, with the EDQM approval serving as a prerequisite for marketing APIs in European Union member states.
